Kyverna reports one-year data for miv-cel in stiff person syndrome and myasthenia gravis
The company said 12-month results from its SPS trial and longer-term follow-up in gMG support a BLA submission on track for completion in Q4 2026.
SEC filing
Latest
3 stories
Thursday, September 24
Tuesday, August 11
Kyverna reports Q2 2026 results and RMAT nod for miv-cel in progressive MS
Kyverna added a third RMAT designation for its CAR T therapy while keeping its stiff person syndrome and myasthenia gravis timelines on track.
SEC filing
Monday, July 27
Kyverna and ElevateBio sign commercial supply deal for miv-cel
The new agreement replaces a prior development pact and covers manufacturing for Kyverna's CAR T-cell therapy as it nears a possible U.S. approval in stiff person syndrome.
SEC filing